Stay updated on Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.

Latest updates to the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter now displays Revision: v3.3.3. The HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2. No substantive study information appears to be changed.SummaryDifference0.1%

- Check41 days agoChange DetectedThe Publications section is now described as automatically filled from PubMed and may not be about the study. The revision label was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the banner notice about a lapse in government funding and the NIH operating status, which previously directed users to opm.gov for status updates. This change affects only operational messaging and does not alter the study details, eligibility criteria, or listed results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange DetectedNo significant changes to the study details, eligibility criteria, outcomes, or enrollment; the updates appear to be formatting/layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

Stay in the know with updates to Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Pexidartinib in Pancreatic/Colorectal Clinical Trial page.